Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Amortization of Deferred Charges (2020 - 2023)

Historic Amortization of Deferred Charges for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$1.7 million.

  • Terns Pharmaceuticals' Amortization of Deferred Charges fell 19734.98% to -$1.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$5.2 million, marking a year-over-year decrease of 653580.25%. This contributed to the annual value of -$2.1 million for FY2024, which is 5990.79% up from last year.
  • Latest data reveals that Terns Pharmaceuticals reported Amortization of Deferred Charges of -$1.7 million as of Q4 2023, which was down 19734.98% from -$1.7 million recorded in Q3 2023.
  • Terns Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $613000.0 during Q1 2022, with a 5-year trough of -$1.7 million in Q3 2023.
  • For the 4-year period, Terns Pharmaceuticals' Amortization of Deferred Charges averaged around -$324307.7, with its median value being -$3000.0 (2021).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 2053333.33% in 2022, then tumbled by 662692.31% in 2023.
  • Over the past 4 years, Terns Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $37000.0 in 2020, then skyrocketed by 424.32% to $194000.0 in 2021, then crashed by 391.75% to -$566000.0 in 2022, then plummeted by 197.35% to -$1.7 million in 2023.
  • Its Amortization of Deferred Charges stands at -$1.7 million for Q4 2023, versus -$1.7 million for Q3 2023 and -$975000.0 for Q2 2023.